Ieq Capital LLC Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Ieq Capital LLC boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 20,749 shares of the medical device company’s stock after buying an additional 730 shares during the quarter. Ieq Capital LLC’s holdings in DexCom were worth $2,353,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom during the 2nd quarter valued at approximately $25,000. Sachetta LLC boosted its position in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. DSM Capital Partners LLC purchased a new stake in shares of DexCom in the fourth quarter worth $28,000. Crewe Advisors LLC bought a new stake in shares of DexCom during the 1st quarter valued at $29,000. Finally, Riverview Trust Co purchased a new position in shares of DexCom during the 1st quarter valued at $32,000. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. UBS Group decreased their target price on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Oppenheimer dropped their price target on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, July 26th. BTIG Research reduced their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Finally, Baird R W lowered shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $112.25.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The disclosure for this sale can be found here. Insiders sold a total of 2,483 shares of company stock worth $201,708 over the last three months. 0.30% of the stock is owned by insiders.

DexCom Stock Down 2.1 %

Shares of NASDAQ:DXCM opened at $70.43 on Friday. The company has a market cap of $28.01 billion, a price-to-earnings ratio of 45.44, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average price of $78.19 and a 200 day moving average price of $109.54.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period last year, the company earned $0.34 EPS. As a group, equities research analysts predict that DexCom, Inc. will post 1.69 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.